Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Bisphosphonates are effective in the management of bone disease in patients with multiple myeloma and recent reports have suggested that they may also have an anti-tumour activity. In support of this, we have previously demonstrated that bisphosphonates can induce myeloma cell apoptosis in vitro; however, it remains unclear whether this occurs in vivo. We have therefore investigated the effect of the potent bisphosphonate ibandronate in the 5T2MM murine model of established multiple myeloma. Short-term treatment with a high dose of ibandronate had no effect on either myeloma cell number or the proportion of myeloma cells undergoing apoptosis. These observations suggest that although bisphosphonates induce apoptosis in myeloma cells in vitro, they may not have the same anti-tumour effects in vivo.

Original publication

DOI

10.1046/j.1365-2141.2000.02310.x

Type

Journal article

Journal

British journal of haematology

Publication Date

10/2000

Volume

111

Pages

283 - 286

Addresses

Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, UK.

Keywords

Bone Marrow Cells, Tumor Cells, Cultured, Animals, Mice, Inbred C57BL, Mice, Multiple Myeloma, Neoplasms, Experimental, Diphosphonates, Treatment Failure, Apoptosis